Search

Displaying results 11 - 15 of 15 in total
  1. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases. … [A262061] Although resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and [entrectinib], there has been no reported case of repotrectinib resistance.

  2. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

  3. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    for example, the IC50 for taletrectinib against ROS1 exhibiting the secondary solvent-front mutation _G2032R_ is 400-times lower than that of the previously approved first-generation inhibitors [crizotinib

  4. Drug

    Amivantamab

    go.drugbank.com/drugs/DB16695
    ApprovedInvestigational

    [A235103,A235118] Amivantamab was found to be more effective than the EGFR inhibitor [erlotinib] or the MET inhibitor [crizotinib] _in vivo_.

  5. Indication

    Metastatic Non-Small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0043377
    Drugs: Adagrasib · Afatinib · Amivantamab · Atezolizumab · Binimetinib · Brigatinib +32 more